SEC Tracker
Get the app
Person · CIK 1681643

Huda Y Zoghbi

Director at Regeneron Pharmaceuticals

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$19.1M
Noticed on Form 144$11M
Bought on Form 4$0
Companies1

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

CompanySecurityHeldShares or unitsAs of
Regeneron Pharmaceuticals REGNCommon StockDirectly1,703Nov 3, 2026 · Filing · EDGAR

Sold and noticed by quarter

Huda Y Zoghbi: dollars sold on Form 4 and noticed on Form 144 per quarter, Q1 2021 to Q4 2026$7.2M$0Q1 2021: $0 noticed on Form 144Q1 2021: $0 sold on Form 4Q2 2021: $0 noticed on Form 144Q2 2021: $0 sold on Form 4Q3 2021: notice not machine-readableQ3 2021: $650K sold on Form 4Q4 2021: $0 noticed on Form 144Q4 2021: $0 sold on Form 4Q1 2022: notice not machine-readableQ1 2022: $1.4M sold on Form 4Q2 2022: $0 noticed on Form 144Q2 2022: $0 sold on Form 4Q3 2022: $0 noticed on Form 144Q3 2022: $0 sold on Form 4Q4 2022: $0 noticed on Form 144Q4 2022: $0 sold on Form 4Q1 2023: $0 noticed on Form 144Q1 2023: $0 sold on Form 4Q2 2023: $0 noticed on Form 144Q2 2023: $0 sold on Form 4Q3 2023: $0 noticed on Form 144Q3 2023: $0 sold on Form 4Q4 2023: $850K noticed on Form 144Q4 2023: $850K sold on Form 4Q1 2024: $1M noticed on Form 144Q1 2024: $1M sold on Form 4Q2 2024: $0 noticed on Form 144Q2 2024: $0 sold on Form 4Q3 2024: $0 noticed on Form 144Q3 2024: $0 sold on Form 4Q4 2024: $0 noticed on Form 144Q4 2024: $0 sold on Form 4Q1 2025: $0 noticed on Form 144Q1 2025: $0 sold on Form 4Q2 2025: $0 noticed on Form 144Q2 2025: $0 sold on Form 4Q3 2025: $0 noticed on Form 144Q3 2025: $0 sold on Form 4Q4 2025: $0 noticed on Form 144Q4 2025: $0 sold on Form 4Q1 2026: $1.3M noticed on Form 144Q1 2026: $1.3M sold on Form 4Q2 2026: $0 noticed on Form 144Q2 2026: $0 sold on Form 4Q3 2026: $640K noticed on Form 144Q3 2026: $640K sold on Form 4Q4 2026: $7.2M noticed on Form 144Q4 2026: $7.2M sold on Form 4Q1 2021Q2 2022Q3 2023Q4 2024Q1 2026

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table
QuarterSold (Form 4)Noticed (Form 144)
Q4 2026$7.2M$7.2M
Q3 2026$640K$640K
Q1 2026$1.3M$1.3M
Q1 2024$1M$1M
Q4 2023$850K$850K
Q1 2022$1.4MNot machine-readable
Q3 2021$650KNot machine-readable
Q3 2020$1.1MNot machine-readable
Q2 2020$5MNot machine-readable

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice dateNoticedPlanned saleOutcomeLinks
Regeneron Pharmaceuticals REGN · UBS Financial Services · No 10b5-1 plan stated · 1 notice
Nov 3, 20267,439 · ~$7.2MNov 3, 2026Sold as noticed Sold 7,439 in 2 sales, Nov 3 to Nov 3 · $7.2M Form 4Filing · EDGAR
Regeneron Pharmaceuticals REGN · UBS Financial Services · 10b5-1 plan adopted Nov 20, 2025 · 2 notices
Aug 10, 2026800 · ~$640KAug 10, 2026Sold as noticed Sold 800 at $800.00 on Aug 10 · $640K Form 4Filing · EDGAR
Feb 19, 20261,638 · ~$1.3MFeb 19, 2026Sold as noticed Sold 1,638 in 11 sales, Feb 19 to Feb 19 · $1.3M Form 4Filing · EDGAR
Regeneron Pharmaceuticals REGN · UBS Financial Services · 10b5-1 plan adopted May 5, 2023 · 2 notices
Jan 2, 20241,117 · ~$1MJan 2, 2024Sold as noticed Sold 1,117 at $900.00 on Jan 2 · $1M Form 4Filing · EDGAR
Oct 13, 20231,000 · ~$850KOct 13, 2023Sold as noticed Sold 1,000 at $850.00 on Oct 13 · $850K Form 4Filing · EDGAR
Sales without a matching Form 144 · 20 sales
No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 2,000 at $675.00 on Mar 16, 2022 · $1.4M (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 998 at $650.00 on Sep 14, 2021 · $649K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 2 at $651.10 on Sep 13, 2021 · $1K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,706 at $650.00 on Jul 7, 2020 · $1.1M (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,706 at $625.00 on Jun 11, 2020 · $1.1M (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 99 at $616.19 on Jun 10, 2020 · $61K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 80 at $615.28 on Jun 10, 2020 · $49K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 5 at $613.03 on Jun 10, 2020 · $3K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 265 at $612.52 on Jun 10, 2020 · $162K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 164 at $611.46 on Jun 10, 2020 · $100K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 202 at $610.41 on Jun 10, 2020 · $123K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 161 at $609.48 on Jun 10, 2020 · $98K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 330 at $608.62 on Jun 10, 2020 · $201K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 251 at $607.64 on Jun 10, 2020 · $153K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 149 at $606.64 on Jun 10, 2020 · $90K (10b5-1 plan)Filing · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 13 at $569.20 on May 7, 2020 · $7KFiling · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 609 at $568.37 on May 7, 2020 · $346KFiling · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 646 at $567.58 on May 7, 2020 · $367KFiling · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 2,128 at $566.37 on May 7, 2020 · $1.2MFiling · EDGAR
———Notice not machine-readable Regeneron Pharmaceuticals (REGN): Sold 1,722 at $565.64 on May 7, 2020 · $974KFiling · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Regeneron Pharmaceuticals REGN Director · filings 2016 to 2026 · sold $19.1M · $11M noticed on Form 144

DateTransactionSharesPriceValueHeld afterSource
Nov 3, 2026Option or RSU exercised or converted+7,439$380.95$2.8M9,142 directFiling · EDGAR
Nov 3, 2026Open-market or private sale−6,939$970.42$6.7M2,203 directFiling · EDGAR
Nov 3, 2026Open-market or private sale−500$971.06$486K1,703 directFiling · EDGAR
Nov 3, 2026Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−7,4390 directFiling · EDGAR
Aug 10, 2026Option or RSU exercised or converted+800$376.69$301K2,503 directFiling · EDGAR
Aug 10, 2026Sale under a 10b5-1 plan−800$800.00$640K1,703 directFiling · EDGAR
Aug 10, 2026Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−8000 directFiling · EDGAR
Feb 19, 2026Option or RSU exercised or converted+1,638$376.69$617K3,341 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−49$774.68$38K3,292 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−50$775.50$39K3,242 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−53$778.47$41K3,189 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−208$779.55$162K2,981 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−331$780.45$258K2,650 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−209$781.28$163K2,441 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−298$782.10$233K2,143 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−220$783.29$172K1,923 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−160$784.45$126K1,763 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−56$785.61$44K1,707 directFiling · EDGAR
Feb 19, 2026Sale under a 10b5-1 plan−4$790.00$3K1,703 directFiling · EDGAR
Feb 19, 2026Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−1,638800 directFiling · EDGAR
Jan 2, 2026Grant or award from the company+1551,703 directFiling · EDGAR
Jan 2, 2026Grant or award from the company
Non-Qualified Stock Option (right to buy)
+1,9621,962 directFiling · EDGAR
Jan 2, 2025Grant or award from the company+1661,548 directFiling · EDGAR
Jan 2, 2025Grant or award from the company
Non-Qualified Stock Option (right to buy)
+1,9581,958 directFiling · EDGAR
Jan 2, 2024Option or RSU exercised or converted+1,117$391.92$438K2,364 directFiling · EDGAR
Jan 2, 2024Sale under a 10b5-1 plan−1,117$900.00$1M1,247 directFiling · EDGAR
Jan 2, 2024Grant or award from the company+1351,382 directFiling · EDGAR
Jan 2, 2024Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−1,1170 directFiling · EDGAR
Jan 2, 2024Grant or award from the company
Non-Qualified Stock Option (right to buy)
+1,6071,607 directFiling · EDGAR
Oct 13, 2023Option or RSU exercised or converted+1,000$391.92$392K2,247 directFiling · EDGAR
Oct 13, 2023Sale under a 10b5-1 plan−1,000$850.00$850K1,247 directFiling · EDGAR
Oct 13, 2023Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−1,0001,117 directFiling · EDGAR
Jan 3, 2023Grant or award from the company+1651,247 directFiling · EDGAR
Jan 3, 2023Grant or award from the company
Non-Qualified Stock Option (right to buy)
+1,9291,929 directFiling · EDGAR
Mar 16, 2022Option or RSU exercised or converted+2,000$391.92$784K3,082 directFiling · EDGAR
Mar 16, 2022Sale under a 10b5-1 plan−2,000$675.00$1.4M1,082 directFiling · EDGAR
Mar 16, 2022Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−2,0002,117 directFiling · EDGAR
Jan 3, 2022Grant or award from the company+1911,082 directFiling · EDGAR
Jan 3, 2022Grant or award from the company
Non-Qualified Stock Option (right to buy)
+2,7072,707 directFiling · EDGAR
Sep 14, 2021Option or RSU exercised or converted+998$391.92$391K1,889 directFiling · EDGAR
Sep 14, 2021Sale under a 10b5-1 plan−998$650.00$649K891 directFiling · EDGAR
Sep 14, 2021Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−9984,117 directFiling · EDGAR
Sep 13, 2021Option or RSU exercised or converted+2$391.92$784893 directFiling · EDGAR
Sep 13, 2021Sale under a 10b5-1 plan−2$651.10$1K891 directFiling · EDGAR
Sep 13, 2021Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−25,115 directFiling · EDGAR
Jan 4, 2021Grant or award from the company+248891 directFiling · EDGAR
Jan 4, 2021Grant or award from the company
Non-Qualified Stock Option (right to buy)
+3,6133,613 directFiling · EDGAR
Jul 7, 2020Option or RSU exercised or converted+1,706$391.92$669K2,349 directFiling · EDGAR
Jul 7, 2020Sale under a 10b5-1 plan−1,706$650.00$1.1M643 directFiling · EDGAR
Jul 7, 2020Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−1,7065,117 directFiling · EDGAR
Jun 11, 2020Option or RSU exercised or converted+1,706$391.92$669K2,349 directFiling · EDGAR
Jun 11, 2020Sale under a 10b5-1 plan−1,706$625.00$1.1M643 directFiling · EDGAR
Jun 11, 2020Option or RSU exercised or converted
Non-Qualified Stock Option (right to buy)
−1,7066,823 directFiling · EDGAR
Jun 10, 2020Option or RSU exercised or converted+1,706$391.92$669K2,349 directFiling · EDGAR
Jun 10, 2020Sale under a 10b5-1 plan−149$606.64$90K2,200 directFiling · EDGAR
Jun 10, 2020Sale under a 10b5-1 plan−251$607.64$153K1,949 directFiling · EDGAR
Jun 10, 2020Sale under a 10b5-1 plan−330$608.62$201K1,619 directFiling · EDGAR
Jun 10, 2020Sale under a 10b5-1 plan−161$609.48$98K1,458 directFiling · EDGAR
Jun 10, 2020Sale under a 10b5-1 plan−202$610.41$123K1,256 directFiling · EDGAR
Jun 10, 2020Sale under a 10b5-1 plan−164$611.46$100K1,092 directFiling · EDGAR

19 earlier transactions are in the filing list below.

All 26 Forms 3, 4, 5 and 144
FiledFormCompanyLinks
Nov 5, 2026Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Nov 3, 2026Form 144Regeneron Pharmaceuticals REGNFiling · EDGAR
Aug 12, 2026Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Aug 10, 2026Form 144Regeneron Pharmaceuticals REGNFiling · EDGAR
Feb 23, 2026Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Feb 19, 2026Form 144Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 6, 2026Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 6, 2025Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 4, 2024Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 2, 2024Form 144Regeneron Pharmaceuticals REGNFiling · EDGAR
Oct 17, 2023Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Oct 13, 2023Form 144Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 5, 2023Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Mar 18, 2022Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 5, 2022Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Sep 15, 2021Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 5, 2021Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jul 8, 2020Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jun 12, 2020Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
May 8, 2020Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 6, 2020Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 4, 2019Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 3, 2018Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Jan 4, 2017Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Sep 12, 2016Form 4Regeneron Pharmaceuticals REGNFiling · EDGAR
Sep 12, 2016Form 3Regeneron Pharmaceuticals REGNFiling · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched . The filing on SEC.gov is the record.